Skip to content

Web-based Screening and Tailored Support

Web-based Screening and Tailored Support for Breast Cancer Patients at the Onset of the Survivorship Phase

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01834521
Acronym
ENCOURAGE
Enrollment
128
Registered
2013-04-18
Start date
2013-01-31
Completion date
2014-12-31
Last updated
2024-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer, psychosocial, website, empowerment

Brief summary

The ever expanding breast cancer survivor population urges the health care system to develop (cost-)effective screening and management of convalescent care needs that can be easily implemented in conventional follow-up care. Internet-delivered systems may be well-equipped to meet these demands. The aim of the current study is to assess the effectiveness of a web-based support system. Key features of this system are patient self-screening of physical and psychosocial problems, tailored patient education on reported problems and self-referral to professional care. In this era of high internet usage, we expect that internet is a highly suitable medium to provide tailored support for breast cancer patients and will empower the patient to take control over their convalescence.

Interventions

OTHERWeb-based screening and tailored support

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult female breast cancer patients (aged ≥ 18 years of age). * Recent completion (≤6 months) of (neo)adjuvant chemotherapy for primary breast cancer * Ability to comprehend Dutch (both reading and writing). * Access to internet (e.g. at home, via family or friends) * Informed consent provided

Exclusion criteria

• Chemotherapy treatment with palliative intent or recurrent breast cancer

Design outcomes

Primary

MeasureTime frameDescription
Change from 6 to 12 weeks follow-up in optimism and control over the future6 and 12 weeksPatients' optimism and control over the future will be measured by the subscale 'increased optimism and control over the future' of the 'Constructs Empowering Outcomes Questionnaire'. The subscale 'optimism and control over the future' represents a single concept/outcome measure. The concept cannot be assessed at baseline due to the retrospective nature of the questionnaire.

Secondary

MeasureTime frameDescription
Change from 6 to 12 weeks follow-up in knowledge level6 and 12 weeksPatient knowledge level will be measured by the subscale 'being better informed' of the 'Constructs Empowering Outcomes Questionnaire'. The concept cannot be assessed at baseline due to the retrospective nature of the questionnaire.
Change from 6 weeks to 12 weeks follow-up in acceptance of problems6 and 12 weeksPatients' acceptance of their problems will be measured by the subscale 'improved acceptance of the illness' of the 'Constructs Empowering Outcomes Questionnaire'. The concept cannot be assessed at baseline due to the retrospective nature of the questionnaire.
Change from baseline to 12 weeks follow-up in quality of lifeBaseline and 12 weeks follow-upCancer-specific quality of life will be measured by the EORTC QLQ-C30 (version 3.0) questionnaire.
Change from baseline to 12 weeks follow-up in psychological distressBaseline and 12 weeks follow-upPsychological distress will be measured by the Dutch Distress Thermometer and Problem List.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026